TMC125-TiDP2-C238: A Randomized, Exploratory, Open-Label 48-Week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-Boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-Experienced HIV-1 Infected Subjects.

Trial Profile

TMC125-TiDP2-C238: A Randomized, Exploratory, Open-Label 48-Week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-Boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-Experienced HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Atazanavir/ritonavir; Etravirine; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TEACH
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
    • 07 Aug 2012 Actual patient number changed from 53 to 52 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top